|
| |
|
and
MEETINGS AT MEMORIAL SLOAN KETTERING CANCER CENTER and
NATIONAL AND INTERNATIONAL
SCIENTIFIC MEETINGS
(AACR, ASCO, ASH) |
|
THE 12TH ANNUAL
BRIAN ROONEY RUN/WALK IN CENTRAL PARK
WAS HELD ON SATURDAY MAY 16, 2009 AT 10AM. THE
RUN/WALK WAS A GREAT SUCCESS WITH A BIG TURNOUT... DESPITE THE CHILLY
OVERCAST DAY... and THE POST RACE PARTY (INCLUDED IN THE ENTRY FEE) THAT
WAS HELD AT THE EAST SIDE TAVERN (LOCATED BETWEEN 82ND AND 83RD STREET ON
FIRST AVENUE) FEATURED DELICIOUS SANDWICH 'WRAPS', FRUIT SALAD, DESERT AND
COOKIES
Proceeds from the
charity run are supplemented by the Lymphoma Foundation to distribute grants
for the support of basic lymphoma cell research, monoclonal
anti-body research for non-Hodgkin's lymphoma and continuing
clinical trials and improvements in stem cell transplantation for
relapsing lymphoma
And for information concerning a
contribution to the Lymphoma Foundation click on the following link
DONATION
RETURN TO HOME PAGE
SCIENTIFIC
MEETINGS AT THE MEMORIAL SLOAN KETTERING CANCER CENTER
PARTICIPANTS AT THE FOLLOWING
MEETINGS AT THE MEMORIAL SLOAN KETTERING CANCER CENTER RECEIVED
PARTIAL GRANT SUPPORT THROUGH THE AUSPICES OF THE LYMPHOMA
FOUNDATION
UPCOMING RESEARCH
MEETING AT THE MEMORIAL SLOAN KETTERING CANCER CENTER
MORTIMER J. LACHER FELLOWS CONFERENCE
Wednesday, June 10, 2009
8:00 – 10:00AM in ZRC-105
Introduction:
Craig Moskowitz,
M.D.
Clinical Director, Division of
Hematologic Oncology
Associate Member, Lymphoma Service
Memorial Sloan Kettering Cancer Center
PRESENTATIONS:
James Hoffman, M.D.
Mentor: Hani Hassoun, M.D.
Light Chain Amyloidosis: Diagnostic Pitfalls and Therapeutic Progress
Todd
Rosenblatt, M.D.
Mentor: Joseph Jurcic, M.D.
Alpha Particle Radioimmunotherapy
of
AML
Jonathan
Schatz, M.D.
Mentors: Dr. Hans-Guido Wendel, M.D.
& Dr. Andrew Zelenetz, M.D., Ph.D.
Emerging Targets: The PIM Family Kinases in Lymphomagenesis and Resistance
to Therapy
Marco Davila, M.D.
Mentor: Michael Sadelain, M.D.,
Ph.D.
Development of a Cell Therapy for B cell Malignancies in Immunocompetent
Mice
Stephanie
Terezakis, M.D.
Mentor: Joachim Yahalom, M.D.
18FDG-PET with CT Scan Co-Registration for Radiation Treatment Planning of
Lymphoma Patients
Concluding Remarks:
Mortimer J. Lacher, M.D.
Consultant, Department of Medicine
Memorial Sloan Kettering Cancer Center
THE LACHER FELLOWS
CONFERENCE JUNE 2008
THE LACHER FELLOWS RESEARCH CONFERENCE OF THE MEMORIAL SLOAN
KETTERING CANCER CENTER WAS HELD ON WEDNESDAY MORNING,
JUNE 11, 2008
– IN THE ROCKEFELLER RESEARCH BUILDING
The following Fellows and their mentors presented the results of
their research of the past year:
James
Hoffman, M.D.
Mentor: Raymond Comenzo, M.D.
CD32B in Plasma
Cell Diseases
Bradford
Hoppe, M.D.
Mentor: Joachim Yahalom, M.D.
The
Role of PET Imaging & Involved-Field Radiotherapy in Relapsed or
Refractory Diffuse Large B cell Lymphoma
Matthew Matasar, M.D.
Mentor: Andrew D. Zelenetz, M.D., PhD
Late Morbidity in
Survivors of Hodgkin’s Lymphoma
Alison Moskowitz,
M.D.
Mentor: Craig Moskowitz, M.D.
Improving Outcomes for
Relapsed & Refractory Hodgkin’s Lymphoma
Todd Rosenblatt, M.D.
Mentor: Joseph Jurcic, M.D.
Alpha-Particle
Immunotherapy for Acute Myeloid Leukemia (AML) With Bismuth-213 and
Actinium 225
The Conference was chaired by Dr. Craig Moskowitz, Clinical
Director, Division of Hematologic Oncology
and Dr. Mortimer J. Lacher provided concluding remarks
SCIENTIFIC
MEETINGS
AT THE MEMORIAL SLOAN KETTERING CANCER CENTER
2007 -
On
June 6, 2007 the Department of Radiation Oncology held a special Grand
Rounds at the Memorial Sloan Kettering Cancer Center to honor the Lymphoma Foundation and Dr.
Mortimer J. Lacher, MD. Brad Hoppe, MD, the
designated Lacher Lymphoma Radiation Oncology Fellow for 2007-2008 presented and
reviewed the data regarding unique treatments of "Relapsed and
Primary Diffuse Large Cell Lymphoma" ... Michelle Klem, MD,
the Radiation Oncology Lacher Fellow 2005-2006 reviewed the current
Consortium results of the Breast Cancer survey of patients
irradiated for Hodgkin's disease. Dr. Joachim Yahalom introduced the
speakers and Dr. Lacher summarized data with regard to secondary
side-effects of radiation and chemotherapy in Hodgkin's patients.
THE LACHER FELLOWS RESEARCH CONFERENCE
WAS HELD AT THE MEMORIAL SLOAN KETTERING CANCER CENTER - THE
ROCKEFELLER RESEARCH LABORATORY BUILDING on WEDNESDAY,
JUNE 13, 2007
- 8:30AM to 11:30AM
Introduction: Tarun Kewalramani, M.D.
Presentations:
Justin Bekelman, M.D.
Mentor: Joachim Yahalom, M.D. and
Deborah Schrag, M.D.
Radiotherapy Quality: Perspectives from Randomized Trials and
Practice
David Chung, M.D., Ph.D.
Mentor: James Young, M.D.
Regulatory T cells Induced by Human Dendritic Cells Expressing
Indoleamine 2, 3-Dioxygenase Suppress Antitumor Immunity
Robert Jenq, M.D.
Mentor: Miguel Perales, M.D.
Combining DNA Tumor Vaccines with Vaccine Adjuvants and Immune
Reconstituting Agents to Enhance Graft versus Tumor Responses after
Allogeneic Bone Marrow Transplantation
Alexander Lesokhin, M.D.
Mentor: Alan Houghton, M.D.
Immunosuppressive Elements in the Tumor Microenvironment
Matt Matasar, M.D., M.S.
Mentor: Andrew Zelenetz, M.D.
Clinical and Pathologic Collaboration between Public Hospitals
and MSKCC in the Management of Lymphoma
Concluding Remarks: Mortimer J.
Lacher, M.D.
2006
- THE
LACHER FELLOWS RESEARCH CONFERENCE WAS HELD AT THE MEMORIAL SLOAN KETTERING
CANCER CENTER - THE ROCKEFELLER RESEARCH LABORATORY BUILDING on WEDNESDAY,
JUNE 7, 2006
Introduction: Tarun Kewalramani, M.D.
Michelle Klem, M.D. - Breast Cancer in Patients Irradiated for
Hodgkin Lymphoma – Mentor – Dr. Joachim Yahalom
Breast Cancer in
Patients Irradiated for Hodgkin Lymphoma: A Review of 92 Cancers in 77
Patients
Michelle L Klem,
M.D., Elena Elkin Ph.D. and Joachim Yahalom, M.D. Memorial Sloan
Kettering Cancer Center, Department of Radiation Oncology INTRODUCTION:
Modern therapy confers excellent survival in Hodgkin lymphoma (HL)
patients. Increased survival after therapy leads to an increase in
detection of the long term consequences of therapy. HL patients who
receive supradiaphragmatic radiation (RT) are at particularly increased
risk for development of breast cancer (BC). Understanding the unique
presentation, treatment options and outcome of this group is important.
METHODS: We performed a review of patients with DCIS or invasive BC
from 1975-2005 who had a history of supradiaphragmatic radiation for HL.
Patients were identified from the center’s database. Local control (LC)
and BC event free survival (EFS) were calculated using the Kaplan Meier
method.
RESULTS: Seventy seven patients had 92 cancers, including 12 bilateral
synchronous and 9 metachronous cases. Median age at radiation for HL was
24 years (range 12-47). Median dose was 39Gy (range 15-48). Sixty one
patients (80%) were under 30 years of age at the time of HL radiation.
Median age at initial BC was 43 years (range 26-61), and median interval
to first BC was 18 years (range 1-40). Twenty two cases were DCIS (24%),
40 stage I (44%), 15 stage II (17%), 10 stage III (11%), and 3 stage IV
(3%). Twenty nine cases were detected by the paient (32%), 6 by
clinician (7%), and 36 on mammogram (39%). Most patients were treated
with unilateral (35) or bilateral (25) mastectomy. Eleven patients
received adjuvant radiation: 7 with external beam, 3 with brachytherapy,
and 1 with combination therapy. In 10 patients who received repeat
radiation, acute toxicity was limited to skin reactions. Of 52 patients
at risk for contralateral BC, 9 developed metachronous lesions (17%).
Median follow up was 3.9 years. Five year LC in treated cancers was
90%. Five year event free survival (EFS) in treated patients was 83%.
CONCLUSIONS:
Most patients who developed BC after radiation for HL had early stage
disease. A significant number of bilateral synchronous and metachronous
lesions were seen. Most patients were treated with unilateral or
bilateral mastectomy, but breast conserving therapy has been employed
with acceptable acute toxicity. More work is needed to elucidate the
clinical outcome of breast cancer in this setting. This study will be
enhanced by matching this cohort with primary BC patients that have not
been irradiated.
John Gerecitano, M.D., Ph.D. - Proteasome Inhibition and the
Treatment of Non-Hodgkin's Lymphomas– Mentor – Dr. Owen O’Connor
INTRODUCTION:
The ubiquitin-proteasome pathway is the
major extralysosomal pathway for the elimination of intracellular
proteins. At the heart of this pathway is the 26S proteasome, which
plays a vital role in degrading regulatory proteins that govern cell
cycle, transcription factor activity, apoptosis and cell trafficking.
Among the key proteins that are temporally degraded by this pathway
during the cell cycle are the cyclins and the cyclin-dependent kinase
inhibitors p21 and p27 Kip1. Both p21 and p27 can induce
cell cycle arrest by inhibiting the cyclin D-, E- and A-dependent
kinases. Interfering with the temporal degradation of these molecules
by blocking proteasome function can thereby arrest the growth of
malignant cells. Another important target of the proteasome is the
Nuclear factor-B (NF-B) signal transduction pathway, which regulates
the expression of adhesion molecules and anti-apoptotic factors.
Bortezomib is a dipeptidyl boronic acid inhibitor with high specificity
for the chymotryptic moiety of the proteasome. Preclinical studies have
demonstrated its ability to prevent proteasome-mediated degradation of
ubiquitinylated proteins, including p16, p21 and IB, and to inhibit
proliferation in many different cancer-derived cell lines. Phase I
studies suggest activity in a variety of neoplasms including lymphoma.
Based on the results of Phase II and III studies in multiple myeloma,
bortezomib has become the first FDA approved proteasome ihibitor for use
in this disease. CURRENT TRIALS:
Our group has shown
that bortezomib has promising activity as a single agent against
indolent lymphomas, even in heavily pretreated patients.
Furthermore, preclinical data in our lab and others have shown that
bortezomib potentiates the effects of cyclophosphamide and rituximab in
a schedule-dependent manner. In
order to exploit the non-cross-resistant mechanism of action of
bortezomib, we are studying it in combination with these other drugs.
Current first line treatments for indolent lymphomas include multi-drug
regimens such as rituximab, cyclophosphamide and prednisone (R-CVP).
Vinca alkaloids have not been shown to have independent activity in
indolent lymphomas, and these agents can cause neuropathy, which is also
the most common dose limiting effect of bortezomib. In the context of a
phase I/II trial, we are sequentially enrolling patients with indolent
lymphoma to be treated with a fixed dose of rituximab, cyclophosphamide
and prednisone and escalating doses of bortezomib. Toxicity of
bortezomib in this multi-drug combination is being closely tracked.
After the maximum tolerated dose (MTD) of bortezomib is determined in
the phase I portion of the trial, patients will be enrolled in the phase
II portion, where response rate and time to relapse will be assessed in
relapsed/refractory patients. In a related study, tissue microarray
analysis is being performed on diagnostic samples from patients treated
with single-agent bortezomib at MSKCC. Immunhistochemistry will be used
to assess the expression profile of proteins involved in signal
transduction, cell cycling, apoptosis and metastasis. This profile will
then be correlated with response to see which pathways may be most
important in the antineoplastic action of bortezomib. Finally, a
second-generation proteasome inhibitor, PR-171, is being tested in a
multicentered phase I trial.
Carlos Ramos, M.D. - Accerlerating Hematopoietic Recovery with
Chemokines – Mentor – Dr. Shahin Rafii/ Dr. Mark Heaney
INTRODUCTION:
Lineage specific cytokines, such as G-CSF, are ineffective in
reconstituting the early phases of hematopoiesis after myelosuppression
induced by radiation or chemotherapy. Our group has shown that
administration of stem cell active chemokines, such as Stromal Derived
Factor 1 (SDF-1) and Fibroblast Growth Factor 4 (FGF-4), promotes rapid
hematopoietic recovery and prevents initial phases of cytopenia induced
by chemotherapy, even in the absence of lineage specific cytokines.
We hypothesized that SDF-1, FGF-4 and their analogues support the
timely reconstitution of hematopoiesis after radiation or
chemotherapy-induced myelosuppression, by promoting rapid recruitment of
stem and progenitor cells from specific bone marrow (BM) niches. In
addition, FGFs and angiogenic factors released in response to SDF-1
likely contribute to the rapid reconstitution of hematopoiesis after
chemotherapy or radiation, by accelerating the regeneration of the BM
vascular network. We assessed the potential for stem cell active
chemokines (SDF-1 analogues and FGF-20) to accelerate hematopoietic
reconstitution after chemotherapy or radiation induced myelosuppression.
Also, we began to determine the mechanisms by which these chemokines and
other angiogenic factors may protect against chemotherapy or radiation
induced myelosuppression, by studying gene expression differences
between wild type animals and specific cytokine knock-outs.
Daniel Persky, M.D. - Biomarkers in Relapsed/Refractory Hodgkin's
Lymphoma – Mentor – Dr. Craig Moskowitz
High dose chemoradiotherapy and ASCT may overcome the prognostic
importance of bcl-2, bim, and p53 overexpression in relapsed/refractory
Hodgkin’s Lymphoma Daniel O. Persky, MD, Alexander Filatov,
MD, Julie Teruya-Feldstein, MD, Tarun Kewalramani, MD, Pauline D.
Bonner, BA, Alexia Iasonos, Ph.D, Andrew D. Zelenetz, MD, Ph.D and Craig
H. Moskowitz, MD. Department of Medicine, Pathology, and Biostatistics,
Memorial Sloan-Kettering Cancer Center, New York, NY
INTRODUCTION:
Approximately twenty percent of patients with Hodgkin’s lymphoma (HL)
relapse or have primary refractory disease. About 50% of these patients
achieve long-term remissions after high-dose chemoradiotherapy and
autologous stem cell transplantation (HDT/ASCT). At MSKCC, ICE (ifosfamide,
carboplatin, etoposide) was incorporated as second-line chemotherapy
prior to HDT/ASCT in a comprehensive treatment program. In addition to
chemosensitive disease, a clinical prognostic model that emerged from
this study identified 3 risk factors - B symptoms at relapse, extranodal
disease, and complete remission duration of less than 1 year (Blood.
2001 Feb 1;97(3):616-23). This model was used to intensify treatment
according to the number of risk factors, with stratification overcoming
the significance of poor prognostic features (Blood. 2003 Nov
16;102(11), abstract #403).
RESULTS: Ninety one patients had sufficient tissue available. Forty
five patients (49%) had disease progression and 36 (40%) died. Median
EFS was 4.7 years, median OS was not reached, and median follow-up was
6.5 years. Bcl-2 was overexpressed in 37/91 (41%), bim in 9/72 (13%),
and p53 in 38/89 (43%) patients. Overexpression of bcl-2, bim, or p53
had no significant association with EFS or OS. Estimated 5-year EFS
rates for positive vs. negative cases were 59% vs 46% for bcl-2, 52% vs
44% for bim, and 47% vs 53% for p53 (all p=NS). The 3 factor clinical
model (B symptoms at relapse, extranodal disease and complete remission
duration of less than 1 year) remained highly significant (0/1 vs 2/3
factors) for EFS and OS (p=0.0005 and p<0.00005, respectively).
CONCLUSION: Despite the evidence that p53 and
bcl-2 over expression may predict a worse prognosis with initial
treatment, it appears that at relapse such over expression is either not
prognostically significant or that the treatment with ICE and HDT/ASCT
overcomes its significance. Further studies will focus on other pathways
that are thought to play a role in relapsed/refractory HL outcomes. Bim
is a novel pro-apoptotic marker from the bcl-2 family that is expressed
on RS cells. Subsequent studies should address its role in both initial
and relapsed/refractory setting.
Conference Summation: Mortimer J. Lacher, M.D.
In his summation, in part,
Dr. Lacher noted the special importance of seeking means to avoid the
radiation induced late onset breast cancers as reported by Dr. Klem, et
al.. In a concise presentation he emphasized the role of reducing the
size and amount of radiation and the controversy surrounding the concept
of completely eliminating radiation therapy in favor of chemotherapy.
MEMORIAL SLOAN KETTERING CANCER
CENTER LACHER FELLOWS SCIENTIFIC MEETING
-
June 2005
At a Special Hematology Oncology Seminar
on Wednesday, June 22, 2005 starting at 8:30AM in the
Rockefeller Research Laboratory Building (Room 116) of the Memorial Sloan
Kettering Cancer Center
the following recipients of the MORTIMER J. LACHER, MD HEMATOLOGY/ONCOLOGY
AND RADIATION THERAPY FELLOWSHIPS (2004-2005) presented their
research of the past year.
Dr. John Gerecitano MD,PhD (mentored by Dr. Owen O'Connor and Dr.
David Spriggs) - Proteasome Inhibition and the Treatment of
Non-Hodgkin's Lymphomas - J. Gerecitano, et al
Dr. Daniel Persky, MD (mentored by Dr. Craig Moskowitz)
The Utility of Upfront High Dose Chemoradiotherapy
and Autologous Stem Cell Transplantation (HDC/ASCT) - D. Persky, et
al
Dr. Deborah Mulford, MD (mentored by Dr. Joseph Juric and Dr. David
Scheinberg) - Antibody based therapy in Acute Myeloid Leukemia - D.
Mulford, et al
Dr. Jeffrey Halaas, MD,PhD (mentored by Dr. Andrew Zelenetz) -
The Follicular International Prognostic Index (FLIPI) is Superior to
WHO/REAL Histological Grade for Identifying High-Risk Patients: A
Retrospective Review of the MSKCC Experience in 260 Patients with
Follicular Lymphoma - J. Halaas, et al
Dr. Welela Tereffe, MD (mentored by Dr. Joachim Yahalom) -
Reduction
of breast, lung, and heart exposure using involved field radiation therapy
for Hodgkin's disease - W. Tereffe, et al
►►THE MORTIMER J. LACHER, MD HEMATOLOGY/ONCOLOGY
AND RADIATION THERAPY FELLOWSHIP RECIPIENTS of the MEMORIAL SLOAN
KETTERING CANCER CENTER
2003-2004 presented the results of their research of the
past year at a
Special Hematology Oncology Seminar on Wednesday, June 16, 2004 in the
Memorial Sloan Kettering Cancer Center Rockefeller Research
Laboratory Building. The following presentations were made by
Dr. Adam Boruchov - Modulation of Fc gamma
receptors on human Dendritic Cells for optimizing immunotherapy
Dr. Jeffrey Halaas - Feasibility and preliminary
efficacy of Rituxin-CHOP-14 in patients with diffuse large B-Cell Lymphoma
Dr. Nicole Lamanna -
Sequential therapy with fludaribine, high dose cyclophosphamide, and
rituximab induces a high incidence of complete response in patients with
chronic lymphocytic leukemia
Dr. Deborah Mulford - Antibody based therapy
for elimination of minimal residual disease in acute myeloid leukemia
Dr. Kathryn Beal - Excellent long term
experience with primary bone lymphoma: Analysis of prognostic factors
►►FOLLOW THIS LINK TO VIEW ABSTRACTS OF THE
LACHER FELLOWS MEETING JUNE 16, 2004
GO TOP
|
|
NATIONAL and INTERNATIONAL SCIENTIFIC MEETINGS
- 2009
American Society of
Clinical Oncology
(ASCO)2009
Phone:
703-299-0150
45th ASCO Annual
Meeting
May 29-June 2, 2009
Orlando, Florida
ABOUT ACCESS TO THE ABSTRACTS:
"NOTE: The 2009 Annual Meeting
Abstracts will be available for viewing on Thursday, May 14 at 6:00 PM EDT. All
presented and publish only abstracts will be included in the launch. The Late
Breaking Abstracts will become available during the Annual Meeting no later than
Sunday, May 31, 12:00 PM EDT. The abstracts can be accessed at
www.abstract.asco.org.
2009 ASCO Electronic Health Records Symposium
Harnessing the EHR: From Incentives to Sustainability
October 6-7, 2009 | San Francisco, CA
San
Francisco Marriott
Lymphoma & Myeloma 2009
An International Congress on Hematologic Malignancies
October 22, 2009 - October 24, 2009
New York, NY
United States
Contact:Customer Service
Phone:770-751-7332
Fax:770-751-7334
E-Mail:meetings@imedex.com
Chair: Morton Coleman, MD
Co-Chairs: John P. Leonard, MD, Ruben Niesvisky, MD, and
Richard R. Furman, MD
American Society of Hematology (ASH)2009
Phone:
202-776-0544
The American
Society of Hematology
51st Annual Meeting and Exposition
December 5-8, 2009
Ernest N. Morial Convention Center
New Orleans, LA
American Association for Cancer Research
(AACR) SPONSORED MEETINGS
CTRC-AACR San Antonio Breast Cancer Symposium
December 9-13, 2009, San Antonio, TX
Abstract submission deadline:
June 15, 2009
The symposium will present a balance of clinical, translational, basic, and
prevention research, providing a forum for interaction, communication, and
education for a broad spectrum of researchers, health professionals, and those
with a special interest in breast cancer. Please make plans to join us in San
Antonio.
Be
sure to save the date for these upcoming AACR conferences:
Metabolism and Cancer
September 13-16, 2009, La Jolla, CA
Frontiers in Basic Cancer Research
October 8-11, 2009, Boston, MA
Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications
October 13-16, 2009, San Diego, CA
Fifth International Conference on Tumor Microenvironment: Progression, Therapy,
and Prevention
October 20-24, 2009, Versailles, France
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
November 15-19, 2009, Boston, MA
Eighth Annual AACR International Conference on Frontiers in Cancer Prevention
Research
December 6-9, 2009, Houston, TX
Genetics and Biology of Brain Cancers
December 13-15, 2009, San Diego, CA
AACR 100th Annual Meeting 2009
MEETING CONCLUDED
April 18 - 22, 2009
Colorado Convention Center
Denver, CO
Phone:
215-440-9300
ABOUT THE MEETING (FROM THE AACR WEBSITE): "The AACR 100th Annual Meeting
2009, with the theme of "Science, Synergy, and Success," highlighted the best
cancer science and medicine from institutions all over the world. The complex
nature of cancer requires an interdisciplinary approach to research. We have
come upon an age when large research teams must work together to make further
progress. The collaborations that naturally ensue from informal interactions at
the AACR Annual Meeting create the synergies that have led to past successes in
the field and will drive research faster toward future cures. The AACR 100th
Annual Meeting 2009 provided an opportunity to stretch your boundaries, attend
sessions outside of your own areas of expertise, and learn how to apply the
exciting new concepts, tools, and techniques to your own research."
GO TOP
|
FUND RAISING EVENTS
FOR THE LYMPHOMA FOUNDATION
A PRO-AM TENNIS MATCH -
FUND RAISING EVENT
ON SUNDAY AFTERNOON APRIL 6, 2008at the BETHPAGE STATE PARK TENNIS CENTER a
successful
charity Pro-Am tennis event in honor of Madeline Fischbach
Zausner (who was under intense chemotherapy treatment at that time) raised funds to
support research grants to be distributed by the Lymphoma
Foundation. The event was well attended and the tennis
professionals David Fischbach (Madeline's son) and Keith Kambourian concluded the
tennis event by hosting a bountiful buffet of various pasta dishes
and deserts.
Madeline
was able to enjoy many months of partial remission of her non-Hodgkin's
lymphoma (that was first diagnosed in July 2007) until September
2008 when the lymphoma progressed in an uncontrollable fashion. Then
Madeline developed the sudden onset of respiratory failure and
despite heroic efforts at resuscitation Madeline died on October 17,
2008.
Dick
Zausner, Madeline's husband, has asked friends and family members to
honor Madeline's memory by sending donations to the Lymphoma
Foundation.
And for information concerning a
contribution to the Lymphoma Foundation click on the following link
DONATION
THE
11TH ANNUAL BRIAN ROONEY RUN/WALK IN CENTRAL PARK, NEW YORK CITY
TOOK PLACE ON SATURDAY MORNING MAY 17, 2008

Proceeds
from the charity run supplemented by the Lymphoma Foundation were distributed
as research grants
for the support of basic lymphoma cell research, monoclonal
anti-body research for non-Hodgkin's lymphoma and continuing
clinical trials and improvements in stem cell transplantation for
relapsing lymphoma
|
The Ninth Annual Lymphoma Foundation Brian Rooney Run/Walk was held
on Saturday May 20th, 2006 in Central Park, New York City and was
enjoyed by an enthusiastic group of 'runners' and 'walkers'.
After the Run they all enjoyed a delicious luncheon buffet at Snapper
Creek. This special event held each spring in memory
of Brian, an avid runner, who died at the age of 32 from non-Hodgkin's
lymphoma... has raised funds each year for the past nine years to support
clinical and basic lymphoma research by Dr. Dennis Cooper, Yale
University, Dr. Gerald Spangrude, University of Utah and Dr. John Leonard,
Cornell University that resulted in adding important data regarding the
basic nature of normal and abnormal lymphocytes, improvements in stem cell
transplantation and the use of newly developed monoclonal antibodies to
treat non-Hodgkin's lymphomas. |
|
This
year's Rooney Run added a special sense of tragedy as well as urgency
toward the accomplishment of its mission as it is marked by the recent
death of Brian's mother who also died from a non-Hodgkin's lymphoma.
Once again... this event convened to raise awareness to the
pressing need to continue to promote and support basic and clinical
treatment knowledge of the lymphomas and allied diseases (e.g. leukemia,
breast cancer, colon cancer, ovarian cancer, NF!, myeloma). to help
determine the genetic nature of the lymphomas... to define the familial
nature of the lymphomas and how can all persons be benefited with
re-adjustment of older forms of treatment and by the application of new
forms of treatment.
Work in progress supported by Lymphoma Foundation
grants addresses these issues: Dr. Offit continues to seek the
answers to the genetic riddle associated with the lymphomas, breast
cancer, colon cancer and the inter-relationship of these tumors and
inheritance and 'normal' aging; Drs. O'Connor, Straus, Comenzo,
Kewalramani, Yahalom, Moskowitz, Sabbatini, Aghajanian, Spriggs, Cooper,
Coleman and Leonard have added new forms of chemotherapy, new protocols
of treatment, and monoclonal antibody therapy to treat the lymphomas and
other cancers; Drs. Spangrude, Counter and Nimer seek basic answers
to the nature of the primary lymphoma cell origins and how cancer cells
and normal cells react to form cancers, age and die (apoptosis) or
resist aging by adjusting the ends of chromosomes called telomeres;
others including Drs. Scheinberg, Jhanwar, Yahalom, and Offit have
concentrated on unique approaches to cancers and blood disorders in
children (leukemia, NF1); Dr. Houghton continues to advance his research
seeking an effective vaccine against the lymphomas and other cancers.
Each of these efforts are 'works in progress' and your support will help
achieve the results that benefit all mankind.
|
|
|
|
GO TOP
A
SPECIAL LYMPHOMA FOUNDATION FUND RAISING
EVENT
was held on May 21, 2005

RUNNERS GATHERED AT THE STARTING LINE
FOR ANOTHER SUCCESSFUL
BRIAN ROONEY RUN/WALK (THE EIGHTH ANNUAL
RUN/WALK) THAT WAS
HELD IN CENTRAL PARK IN NEW YORK CITY ON SATURDAY MAY21, 2005 AT 10AM
This special event held each spring in
memory of Brian, an avid runner, who died at the age of 32 from
non-Hodgkin's lymphoma... has raised funds each year for the past eight
years to support clinical and basic lymphoma research.
|

Some of the wonderful volunteers setting up the 'sign
in' booth early in the morning before the runners arrive. |

Colin, Tricia and Diana getting ready to 'run'
|

Andrew... waiting for the runners to cross the finish
line |
|
EVENTS - 2004
►►THE BRIAN ROONEY RUN WALK OF 2004
►►FOLLOW THIS LINK
TO VIEW
SELECTED ABSTRACTS FROM
THE 40TH ANNUAL AMERICAN SOCIETY OF CLINICAL ONCOLOGISTS (ASCO) MEETING in June 5-8,
2004
|
|
The Annual Spring Time Brian
Rooney Run/Walk in Central Park, New York City

The 2002 Logo for the Brian Rooney Run/Walk in Central Park
The Annual Brian Rooney Run/Walk in Central Park raises research funds for
the Lymphoma Foundation in honor and memory of Brian Rooney who died at a
young age from non-Hodgkin's lymphoma. The family and friends of Brian Rooney
generously donate their time and resources to make this tribute to Brian a
success each year it has been run since 1997
|
|
UPDATE:
ON A HAZY, SUNNY MORNING IN CENTRAL PARK IN NEW YORK CITY
ON SATURDAY, MAY 22, 2004
THE 7TH ANNUAL BRIAN ROONEY RUN/WALK
WAS ATTENDED BY MANY FAMILY MEMBERS AND FRIENDS OF BRIAN ROONEY AND FRIENDS OF
THE LYMPHOMA FOUNDATION. (CLICK ON THIS LINK TO ACCESS ADDITIONAL PHOTOS FROM THE EVENT). BECAUSE OF THE GENEROSITY OF SO MANY
VOLUNTEERS AND DONORS... FUNDS WERE RAISED FOR RESEARCH GRANTS THAT WILL
EVENTUALLY LEAD TO THE CURE OF ALL PATIENTS WITH LYMPHOMA AND ALLIED DISORDERS. |
|
 Andrew Bresnahan and Tricia Cooney Bresnahan
have been the coordinators of the Run/Walk each year and this year (2004) their
first child Colin Andrew Bresnahan (born October 14, 2003) joined the Run/Walk
with his parents... although we must tell you that Colin did more sleeping than
running or walking.
|
|
The Brian Rooney RUN\WALK 2004 was also attended by many children and
their
family pets. While Colin Bresnahan rested, Melody, the 'little red
dog', tore away from his mistress and came in at the finish line just ahead of
two contenders for the slow-time award!
|
 |
In the year 2000 it was sunny and nice. In 2002 it was freezing cold and
raining although you couldn't tell that from the up-beat logo of 2002.
On May 17, 2003 it was overcast in the morning and then
sunny later in the day. Some believe that the best part of the
Run/Walk is after the 'race' when everyone gathers at the Snapper Creek Tavern
on First Avenue between 82nd and 83rd Street to enjoy a wonderful repast of tasty
sandwiches, pasta, fruit, cake and cookies hosted by Brian's old friends the
owners of Snapper Creek.

WITH THE ASSISTANCE OF GRANTS FROM THE
ROONEY FUND OF THE LYMPHOMA FOUNDATION...we have been able to support
valuable lymphoma research by clinician/scientists including Dr. Dennis Cooper,
Director of the Stem Cell Transplant Program, Yale Cancer Center, Yale University Medical School, Dr. Janet Cuttner and Dr. Janice
Gabrilove, Mount Sinai Medical Center, New York City and
Dr. Gerald Spangrude, Professor of Oncological Sciences, Department of
Hematology, University of Utah School of Medicine, Salt Lake City.
Acknowledging grant support by the Brian Rooney Fund of the Lymphoma Foundation
the following research papers were published:
Allogenic Peripheral Blood Stem Cell Transplantation for High-risk
Non-Hodgkin's Lymphoma S. Seropian, E. Bahceci and D. L. Cooper from the
Section of Medical Oncology, Department of Internal Medicine, Yale University
School of Medicine, New Haven, CT. Their experience with poor prognosis patients
with Non-Hodgkin's lymphoma to improve the outcome of allografting indicated
that patients who relapse after an autologous transplant can be salvaged with an
allogenic transplant. Bone Marrow Transplantation (2003) 32, 763-769
Characterization of Thymic Progenitors in Adult Mouse Bone Marrow S.
Scott Perry, L. Jeanne Pierce, William B. Slayton, and Gerald J. Spangrude from
the Departments of Pathology, Pediatrics, Oncological Sciences and Hematology:
University of Utah Medical Center. They described the phenotype of an adult
mouse bone marrow population highly enriched for rapidly engrafting, long-term
thymocyte progenitors and noted that the disparity in B and T cell expansion
from this lymphoid progenitor population suggests it contains the progenitor
responsible for seeding the thymus throughout life. The Journal of
Immunology, 2003, 170:1877-1886
Early Stages of
Hematopoietic Differentiation G. J. Spangrude, S. Scott Perry, and
W.B.Slayton Departments of Oncological Sciences, Pathology, Pediatrics, and
Medicine, Division of Hematology: University of Utah Medical Center, Salt Lake
City, Utah. They concluded: The potential of defined cell populations to
differentiate as T or B lymphocytes in vivo was dependent upon the time
post transplant at which animals were evaluated. These studies underscore the
need for caution in the interpretation of lineage potentials evaluated by both
in vitro and in vivo assays. Ann. N.Y. Acad. Sci. 996:186-194
(2003)
Aspects of Early
Lymphoid Commitment H. Wang, and G. J. Spangrude. Departments of
Pathology, Oncological Sciences and Medicine, Division of Hematology, University
of Utah, Salt Lake City, Utah. They reviewed the progress "in understanding the
molecular under pinning of commitment to the lymphoid pathways of
differentiation..." Current Opinion in Hematology 2003, 10:203-207
NOTE: The Rooney Fund
of the Lymphoma Foundation recently funded Dr. Scott Perry in Dr. Spangrude's
laboratory and is now funding the career development of Dr. H. Wang. Her research is directed toward identifying molecules that may play important roles in
early hematopoiesis (blood production) and may also function as targets for
oncogenic (cancer) transformation in the T and B lymphocyte cell lineages.
|
|
It's Ancient History now... but the OCTOBER 10th, 2002
GALA DINNER is still in our memory and we hope to be able to
repeat its success at a future date.
On October 10, 2002 a Gala Fund Raising Dinner at Taste, Eli Zabar's Restaurant on Third Avenue and 80th Street in Manhattan, was successful in raising much needed research funds. The Dinner was coordinated by Diana Berner, the Executive
Administrator of the Lymphoma Foundation. The first notices were sent out in
June 2002 followed by an up-dated notice to the participants as all the
arrangements were being completed. It was a hectic period with some uncertainty
as the restaurant was closed for a complete renovation for three months and
re-opened just in time for the Lymphoma Foundation affair a few days before October 10th.
OCTOBER 10, 2002
GALA DINNER
SPECIAL THANKS TO OUR
GALA DINNER COMMITTEE MEMBERS
ROBERT P. CASTRIGNANO
JOAN AND WILLIAM R. GRUVER
KAREN AND JEFFERSON HUGHES
JOYCE AND ROBERT MENSCHEL
LISA AND ANTHONY SCARAMUCCI
DEANNE AND EDWARD SPIEGEL
ADRIENNE AND MARTIN ZAUSNER
AND FOR THE GENEROUS
SUPPORT OF THIS GALA DINNER BY ALL OF OUR GUESTS AND ESPECIALLY
SANDY and ELLEN LEVIN
WILLIAM SAFIRE
SHARON AND FRED STEIN
WILLIAM D. ZABEL, ESQ.
|
Numerous smaller dinner and luncheon gatherings
are held all year long to introduce the clinician/scientists and their
research to the generous
donors who enable the Lymphoma Foundation provide the grants that are so
important in promoting their innovative cancer research.
GO TOP
|
|
|
|
HOME
SCIENTISTS
RESEARCH
EVENTS
BOARD
FELLOWS BREAST
CANCER
HEART DISEASE
PUBLICATIONS CONTACT
US |
|

The
Lymphoma Foundation is a nationwide not for profit foundation dedicated to
funding clinical and basic laboratory cancer research and applying the
knowledge developed by the clinician scientists for the general welfare
and education of all cancer patients. |
|
© Copyright THE LYMPHOMA
FOUNDATION All rights reserved
|
|